[Effect of urapidil therapy on insulin, glucagon, gastrin and pancreatic polypeptide secretion in patients with idiopathic arterial hypertension].
Zukowska-Szczechowska
E
E
Kokot
F
F
Grzeszczak
W
W
Wiecek
A
A
D000328:Adult; D000959:Antihypertensive Agents; D005260:Female; D005755:Gastrins / Q000378:metabolism*; D005934:Glucagon / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D010187:Pancreatic Hormones / Q000378:metabolism*; D010191:Pancreatic Polypeptide / Q000037:antagonists & inhibitors / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D013268:Stimulation, Chemical
D000959:Antihypertensive Agents; D005755:Gastrins; D007328:Insulin; D010187:Pancreatic Hormones; D010879:Piperazines; D010191:Pancreatic Polypeptide; D005934:Glucagon; C015568:urapidil
Wpływ leczenia urapidilem na wydzielanie insuliny, glukagonu, gastryny i polipeptydu trzustkowego u chorych na samoistne nadciśnienie tetnicze.